Our aim in the present study was to explore the role of silent inflammation in MS pathophysiology by studying the correlation between CSF IL-1β content at the time of clinical and radiological remission with markers of disease activity, disability progression and neuronal damage [22,23] at midterm follow-up. This evidence concerns the gene IL1B and myeloid sarcoma.